Type 2 Diabetes + CKD Clinical Guide 2026

Managing type 2 diabetes in a patient with chronic kidney disease requires more than simply lowering A1C.

This practical 41-page clinical guide helps you connect glycemic control, kidney protection, cardiovascular risk reduction, renal dosing, monitoring, and patient-specific treatment decisions into one clear approach.

Built for pharmacy learners and healthcare professionals who want to move from memorizing guidelines to actually applying them in patient care.

What's Inside

• Quick-start T2DM + CKD patient workup
• CKD staging using eGFR and UACR
• Individualized A1C and blood pressure goals
• Metformin use and renal considerations
• SGLT2 inhibitor selection, dosing, safety, and counseling
• GLP-1 therapy and kidney/CV outcomes
• ACE inhibitor and ARB management
• Finerenone dosing, potassium monitoring, and patient selection
• Other glucose-lowering medications in CKD
• Practical medication-selection algorithm
• Renal dosing and monitoring tables
• 5 clinical patient cases with reasoning
• Patient counseling points
• Pharmacist workup checklist
• Clinical pearls and common medication mistakes
• Guideline and primary-literature references

Built for Clinical Application

Instead of focusing only on individual medications, this guide helps answer questions such as:

What therapy should I prioritize?
Does this medication need renal adjustment?
What should I monitor after starting therapy?
Is kidney-protective therapy missing even if the A1C is controlled?
When should therapy be intensified or deintensified?

The guide includes a practical treatment pathway, medication thresholds, monitoring strategies, and case-based examples designed to help you work through the whole patient, not just a laboratory value.

Evidence-Based for 2026

The guide incorporates the 2026 ADA Standards of Care, KDIGO guidance, U.S. prescribing information, and major kidney and cardiovascular outcome trials, including evidence involving SGLT2 inhibitors, GLP-1 therapy, and finerenone.

Version 1.1 | 2026 Edition
41-page digital PDF
Evidence reviewed through August 25, 2026

For educational use only. This resource does not replace patient-specific clinical judgment, current prescribing information, institutional policy, or applicable clinical guidelines.